StockData
Bright Minds Biosciences Inc. logo

Bright Minds Biosciences Inc. (DRUG) shareholders

DRUGNasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Sep 30, 2025Last filing: 40-F on Dec 23, 2025Score 5/30
$20.76+0.25 (+1.22%)

Close on Nov 18, 2026Market cap $158.52MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
100.0%
9M of 8M shares
Institutional holders
100
20 new, 12 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 1 sales
Net sold $9.79M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Ian McDonald1,396,66513.70%13D (active) amendmentNov 4, 2024
Janus Henderson Group PLC1,284,32413.10%13G (passive) amendmentMar 31, 2026
Cormorant Asset Management, LP
Joint filing with Bihua Chen (10.88%)
1,059,33110.88%13G (passive) amendmentJan 31, 2026
Chen Bihua
Joint filing with Cormorant Asset Management, LP (9.71%)
950,0009.71%13G (passive) amendmentApr 28, 2026
Bihua Chen
Joint filing with Cormorant Asset Management, LP (9.17%)
900,0009.17%13G (passive) amendmentJun 30, 2026
Vivo Opportunity, LLC
Joint filing with Vivo Opportunity Fund Holdings, L.P. (5.20%)
504,6455.20%13G (passive) amendmentMar 31, 2026
Vestal Point Capital, LP
Joint filing with Ryan Wilder (5.00%)
492,3195.00%13G (passive)Mar 31, 2026
Vivo Opportunity Fund Holdings, L.P.
Joint filing with Vivo Opportunity, LLC (6.40%)
454,1846.40%13G (passive)Sep 30, 2025
Perceptive Life Sciences Master Fund, Ltd.
Joint filing with Perceptive Advisors LLC (6.30%), Joseph Edelman (6.30%)
444,6496.30%13G (passive) amendmentMar 31, 2025
Adage Capital Management, L.P.
Joint filing with Robert Atchinson (5.58%), Phillip Gross (5.58%)
395,7435.58%13G (passive)Sep 30, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of DRUGValueChange% of portfolio
Jupiter Topco LLC1,349,10717.67%$94.82MNew0.04%
Cormorant Asset Management, LP900,00011.79%$63.18M−159,3313.24%
BlackRock, Inc.686,1848.99%$48.17M+64,2510.00%
Vivo Capital, LLC557,1727.30%$39.11M–3.57%
Vestal Point Capital, LP545,0007.14%$38.26M+52,6810.89%
Braidwell LP483,8226.34%$33.96M−55,8861.26%
Driehaus Capital Management LLC433,3775.68%$30.42M+8620.18%
Balyasny Asset Management L.P.345,0534.52%$24.22M+47,8950.03%
Adage Capital Partners Gp, L.L.C.335,0004.39%$23.52M−160,7430.03%
Point72 Asset Management, L.P.327,4164.29%$22.98MNew0.03%
Deerfield Management Company, L.P. (Series C)283,0003.71%$19.87M–0.21%
Ra Capital Management, L.P.265,0003.47%$18.60M–0.16%
Parkman Healthcare Partners LLC205,0532.69%$14.39M+164,9551.47%
Mpm Bioimpact LLC202,1142.65%$14.19M−10,0610.87%
Wellington Management Group Llp171,3152.24%$12.03M+34,6380.00%
Goldman Sachs Group Inc133,6891.75%$9.38M+59,3200.00%
Eventide Asset Management, LLC130,0131.70%$9.13M–0.12%
State Street Corp122,1781.60%$8.58M+13,9390.00%
Seven Grand Managers, LLC120,0001.57%$8.42M–0.34%
Great Point Partners LLC109,6031.44%$7.69M−110,3971.45%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20261009M100.0%20 / 4717 / 123M1M
Q1 2026949M100.0%29 / 4515 / 73M0M
Q4 2025747M86.3%17 / 2720 / 71M1M
Q3 2025646M79.2%18 / 2213 / 11M0M
Q2 2025475M68.6%22 / 79 / 90M0M
Q1 2025345M68.3%10 / 108 / 71M1M
Q4 2024315M64.1%26 / 22 / 15M0M
Q3 202460M2.5%2 / 21 / 10M0M
Q2 202460M2.6%0 / 12 / 10M0M
Q1 202470M2.8%3 / 11 / 40M0M
Q4 202380M3.0%2 / 31 / 00M0M
Q3 202360M2.5%6 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

87 funds held DRUG in Q2 2026, 44% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of DRUGValue% of fundAs of
iShares Russell 2000 ETF194,4172.55%$13.65M0.02%Jun 30, 2026
Eventide Healthcare & Life Sciences Fund130,0131.70%$9.13M0.51%Jun 30, 2026
BlackRock Health Sciences Opportunities Portfolio95,6551.25%$8.42M0.14%May 29, 2026
Fidelity Small Cap Index Fund81,2311.06%$5.95M0.02%Jul 31, 2026
iShares Russell 2000 Growth ETF69,5910.91%$4.89M0.03%Jun 30, 2026
Driehaus Micro Cap Growth Fund41,5680.54%$2.92M0.49%Jun 30, 2026
Vanguard Russell 2000 Index Fund35,8790.47%$3.16M0.02%May 31, 2026
Vanguard U.S. Momentum Factor ETF28,8820.38%$2.54M0.14%May 31, 2026
iShares Micro-Cap ETF24,9190.33%$1.75M0.12%Jun 30, 2026
AdvisorShares Psychedelics ETF24,2740.32%$1.70M3.84%Jun 30, 2026
Blackstone Alternative Multi-Strategy Fund22,2670.29%$1.56M0.04%Jun 30, 2026
Adara Smaller Companies Fund20,2380.27%$1.78M0.22%May 31, 2026
Goldman Sachs Small Cap Equity Insights Fund18,8150.25%$1.38M0.14%Jul 31, 2026
Schwab Small-Cap Index Fund18,0320.24%$1.32M0.02%Jul 31, 2026
Master Small Cap Index Series13,8520.18%$972.41K0.02%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Bihua Chen–452,4095.92%Apr 30, 2026
Cormorant Global Healthcare Master Fund, LP–864,74311.32%Apr 30, 2026
Cormorant Asset Management, LP–950,00012.44%Apr 30, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Cormorant Asset Management, LP
–
Apr 28, 2026Sale−109,331$89.50$9.79M950,000
Cormorant Asset Management, LP
10% owner
Nov 4, 2024Buy+184,331$21.70$4.00M1,059,331
Cormorant Global Healthcare Master Fund, LP
10% owner
Oct 16, 2024Buy+39,743$23.22$922.83K864,743
Cormorant Global Healthcare Master Fund, LP
10% owner
Oct 16, 2024Buy+3,107$25.22$78.36K875,000
Cormorant Global Healthcare Master Fund, LP
10% owner
Oct 16, 2024Buy+7,150$24.03$171.81K871,893
Cormorant Global Healthcare Master Fund, LP
10% owner
Oct 15, 2024Buy+4,609$12.35$56.92K825,000
Cormorant Global Healthcare Master Fund, LP
10% owner
Oct 15, 2024Buy+19,169$11.72$224.66K820,391
Cormorant Global Healthcare Master Fund, LP
10% owner
Oct 15, 2024Buy+2,700$9.26$25.00K801,222
Cormorant Global Healthcare Master Fund, LP
10% owner
Oct 15, 2024Buy+8,900$7.31$65.06K795,922
Cormorant Global Healthcare Master Fund, LP
10% owner
Oct 15, 2024Buy+33,343$6.42$214.06K787,022
Cormorant Global Healthcare Master Fund, LP
10% owner
Oct 15, 2024Buy+63,173$5.92$373.98K753,679
Cormorant Global Healthcare Master Fund, LP
10% owner
Oct 15, 2024Buy+238,097$4.53$1.08M690,506
Cormorant Global Healthcare Master Fund, LP
10% owner
Oct 15, 2024Buy+2,600$8.80$22.88K798,522

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
1M shares short
Days to cover
7.9
At 0M shares a day
Change since last report
-3.4%
From 1M shares
Short volume, 20 days
42.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Bright Minds Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 93,618 shares on Oct 8, 2026 over the last 90 days.

See a number that looks wrong?